Clinical Trial Update: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial of bendamustine hydrochloride in previously treated multiple myeloma and plasma cell leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Status: WITHDRAWN